Ads
related to: mbrx stock
Search results
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
Zacks via Yahoo Finance· 8 months agoMoleculin (MBRX) completes enrollment in the phase II portion of the development program for its...
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo Finance· 1 year agoMoleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects,...
Companies Like Moleculin Biotech (NASDAQ:MBRX) Are In A Position To Invest In Growth
Simply Wall St. via Yahoo Finance· 2 years agoJust because a business does not make any money, does not mean that the stock will go down. For...
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoMoleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2023 Earnings Call Transcript March 25, 2024 Moleculin...
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Simply Wall St. via Yahoo Finance· 5 months agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
What's Going On With Moleculin Biotech Stock Today?
Benzinga via Yahoo Finance· 1 year agoMoleculin Biotech Inc (NASDAQ: MBRX) announced that preclinical data regarding its next-generation anthracycline, Annamycin, was presented at the...
Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies
Benzinga via Yahoo Finance· 2 years agoMoleculin Biotech Inc (NASDAQ: MBRX) announced that its WP1096 molecule would be evaluated in animal...
Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate
Benzinga via Yahoo Finance· 1 year agoMoleculin Biotech Inc (NASDAQ: MBRX) provided an update on its clinical programs evaluating...
MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates
InvestorPlace via Yahoo Finance· 1 year agoMoleculin Biotech (NASDAQ:MBRX) reported first quarter results for 2023. Moleculin Biotech reported a loss per share of 28 cents. That was worse than the analyst estimate for a loss of 25 cents ...
Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting
Benzinga via Yahoo Finance· 1 year agoMoleculin Biotech Inc (NASDAQ: MBRX) announced the topline results from its MB-105 European Phase 1...
